EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management

Corey Keith Goldman, Jesse M Goldman

The Journal of Clinical Hypertension · 2026

DOI: 10.1111/jch.70353 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Hypertension, 2026. Verfasst von Corey Keith Goldman und 1 weiteren Autor:innen. Beteiligte Einrichtung: NYU Langone Health, MedAlliance Medical Health Centers, Bronx, New York, USA. Hauptthemen laut MEDLINE: Endothelin Receptor Antagonists, Hypertension, Proteinuria, Renal Insufficiency, Chronic. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This narrative review examines how endothelin receptor antagonists (ERAs) can be used at the intersection of difficult‐to‐control hypertension, chronic kidney disease (CKD), and albuminuria or proteinuria. For clinicians, the central question is not receptor selectivity alone, but whether a specific agent, indication, dose, background therapy, and monitoring plan can deliver meaningful blood‐pressure or kidney benefit without unacceptable fluid retention. Pulmonary arterial hypertension established the pharmacology and major safety liabilities of the class; the current implementation questions for hypertension and kidney specialists arise in systemic hypertension and proteinuric kidney disease. Aprocitentan is the first and only ERA approved for hypertension; in PRECISION, the approved 12.5‐mg once‐daily dose reduced placebo‐corrected 24‐h ambulatory systolic blood pressure by 4.2 mm Hg, with reductions of 4.2 to 5.9 mm Hg across the studied doses. In IgA nephropathy (IgAN), sparsentan reduces proteinuria and slows estimated glomerular filtration rate (eGFR) decline. Atrasentan has an established antiproteinuric effect and a favorable eGFR slope, although the prespecified week‐136 eGFR contrast in the final ALIGN analysis did not reach statistical significance. Zibotentan plus dapagliflozin remains investigational. Across these settings, successful ERA use depends on careful patient selection, indication‐specific interpretation of the evidence, optimized diuretic and cardiorenal therapy, and early surveillance for edema, anemia, liver‐test abnormalities, and pregnancy risk, with treatment interruption or discontinuation when clinically significant volume expansion or other serious safety signals occur.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelin Receptor AntagonistsHypertensionProteinuriaRenal Insufficiency, ChronicHumansAntihypertensive AgentsAtrasentanGlomerular Filtration RateFemalePyrrolidinesBlood PressureGlomerulonephritis, IGADrug ResistancePyrimidinesSulfonamides

Stichwörter der Autor:innen

IgA nephropathyaprocitentanchronic kidney diseaseedemaendothelin receptor antagonistproteinuriaresistant hypertensionvolume management

Substanzen

Endothelin Receptor AntagonistsAntihypertensive AgentsAtrasentanaprocitentanPyrrolidinesPyrimidinesSulfonamides

Autor:innen und Institutionen

  • NYU Langone Health, MedAlliance Medical Health Centers, Bronx, New York, USA.
  • Clinical Professor of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Zitieren

APA

Goldman, C. K., & Goldman, J. M. (2026). Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70353

Vancouver

Goldman CK, Goldman JM. Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management. The Journal of Clinical Hypertension. 2026. doi:10.1111/jch.70353

BibTeX
@article{Goldman2026,
  author = {Goldman, Corey Keith and Goldman, Jesse M},
  title = {Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management},
  journal = {The Journal of Clinical Hypertension},
  year = {2026},
  doi = {10.1111/jch.70353}
}
Kostenlos starten →